2021 12AUG Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply posted by admin in Latest News Read More 2021 24JUN Elevation Oncology Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2021 15JUN RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer posted by admin in Latest News Read More 2021 08JUN Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S. posted by admin in Latest News Read More 2021 03JUN venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences posted by admin in Latest News Read More 2021 26MAY NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial posted by admin in Latest News Read More 2021 14MAY Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) posted by admin in Latest News Read More 2021 10MAY Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives posted by admin in Latest News Read More 2021 22APR Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering posted by admin in Latest News Read More 2021 09MAR Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs posted by admin in Latest News Read More 2021 01MAR FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform posted by admin in Latest News Read More 2021 26FEB Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies posted by admin in Latest News Read More 2021 28JAN Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies posted by admin in Latest News Read More 2021 08JAN Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients posted by admin in Latest News Read More 2021 05JAN Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO posted by admin in Latest News Read More 2020 08DEC Barely two months after unveiling a new breed of radiopharmaceuticals, RayzeBio brings total haul to $150M posted by admin in Latest News Read More 2020 01DEC Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer posted by admin in Latest News Read More 2020 18NOV Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer posted by admin in Latest News Read More 2020 18NOV Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE posted by admin in Latest News Read More 2020 13NOV Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE posted by admin in Latest News Read More 2020 09NOV Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients posted by admin in Latest News Read More 2020 09NOV ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors posted by admin in Latest News Read More 2020 14OCT RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics posted by admin in Latest News Read More 2020 14OCT Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy posted by admin in Latest News Read More 2020 15SEP Metacrine Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2020 14SEP Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis posted by admin in Latest News Read More 2020 18AUG Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering posted by admin in Latest News Read More 2020 06AUG Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2020 16JUL ALX Oncology Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2020 30JUN Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients posted by admin in Latest News Read More 2020 26JUN Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer posted by admin in Latest News Read More 2020 10JUN Checkmate Pharmaceuticals Secures $85 Million in Series C Financing posted by admin in Latest News Read More 2020 09JUN NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis posted by admin in Latest News Read More 2020 08APR Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA posted by admin in Latest News Read More 2020 03APR venBio Closes $394 Million Life Sciences Venture Capital Fund posted by admin in Latest News Read More
2020 31MAR All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study posted by admin in Latest News Read More 2020 12FEB ALX Oncology Announces Closing of $105 Million Series C Financing posted by admin in Latest News Read More 2020 08JAN NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic posted by admin in Latest News Read More 2020 07JAN Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) posted by admin in Latest News Read More 2019 05NOV Checkmate Pharmaceuticals Presents Positive Clinical Data with CMP-001 posted by admin in Latest News Read More 2019 03OCT Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors posted by admin in Latest News Read More 2019 10SEP Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema posted by admin in Latest News Read More 2019 15AUG Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant) posted by admin in Latest News Read More 2019 19JUN Akero Therapeutics Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2019 18APR Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA posted by admin in Latest News Read More 2019 17APR Turning Point Therapeutics prices IPO at $18, the high end of the range posted by admin in Latest News Read More 2019 27MAR Precision BioSciences Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2019 12FEB Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant posted by admin in Latest News Read More 2018 12DEC Akero Therapeutics Announces $70 Million in New Financing posted by admin in Latest News Read More 2018 06DEC Impel NeuroPharma Closes $67.5 Million Series D Financing posted by admin in Latest News Read More 2018 27NOV Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy posted by admin in Latest News Read More 2018 07NOV ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors posted by admin in Latest News Read More 2018 19OCT TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners posted by admin in Latest News Read More 2018 25JUN Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases posted by admin in Latest News Read More 2018 17APR TLR9 Agonist CMP-001-Pembrolizumab Combination Shows Early Efficacy in Patients With Metastatic Melanoma Resistant to Anti-PD-1 posted by admin in Latest News Read More 2018 24JAN Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock posted by admin in Latest News Read More 2018 04JAN Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept posted by admin in Latest News Read More 2017 08NOV Apellis Pharmaceuticals Announces Pricing of Initial Public Offering posted by admin in Latest News Read More 2017 05OCT Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing posted by admin in Latest News Read More 2017 18JUL venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough posted by admin in Latest News Read More 2017 15JUNE Checkmate Pharmaceuticals Secures $27 Million Series B Preferred Financing and Appoints Karen Brennan as Chief Operating Officer posted by admin in Latest News Read More 2017 10APR Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma posted by admin in Latest News Read More 2016 02DEC Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform for Central Nervous System Disorders posted by admin in Latest News Read More 2016 29NOV Nabriva Announces Terms of Rights Offering posted by admin in Latest News Read More 2016 06MAY venBio Closes $315 Million Life Sciences Venture Capital Fund posted by admin in Latest News Read More 2016 27MAR Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology posted by admin in Latest News Read More 2016 12FEB Apellis Completes $47 Million Series D Financing posted by admin in Latest News Read More 2015 12AUG Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment For Development of Novel Immuno-Oncology Product Platform posted by admin in Latest News Read More 2015 05AUG Metacrine Raises $36M in VC Funding, Focuses on Metabolic Diseases posted by admin in Latest News Read More 2015 11MAY Precision BioSciences Lands $26M for Gene-Editing Technology posted by admin in Latest News Read More 2014 02JUL VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma posted by admin in Latest News Read More 2014 01JUL Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals posted by admin in Latest News Read More 2014 10JUN As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund posted by admin in Latest News Read More